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The criteria and terminology for diagnosing interstitial lung disease (ILD), a diverse range of pulmonary fibrotic disorders that affect
the alveoli of the lungs, have been variable and confusing; however, there have been recent major improvements to an internationally
agreed classification. Evidence from recent analyses of populations suggests that the incidence and prevalence rates of ILD are on the
increase, particularly when the broad definition of ILD is used. In most patients with ILD a cause is not identified; nevertheless, among
the established causes are a number of drug therapies and infections. Occupational causes are lessening in importance, while cigarette
smoking is now an established risk factor. Radiation therapy for cancer is a well-established cause of ILD that usually, but not always,
localises within the radiation portal and may occur later after completion of therapy. Similarly, exposure to drugs long after radiation
therapy may be an aetiological factor for the development of ILD later in life, although the magnitude of this risk requires further
epidemiological investigation. The possibility that ILD and lung cancer are associated has been recognised for 450 years, but it
remains unclear whether ILD precedes lung cancer or vice versa. In this review, we examine the epidemiology of ILD and the basis for
its association with lung cancer.
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INTRODUCTION
Interstitial lung disease (ILD) refers to a diverse range of
pulmonary fibrotic disorders that affect the alveoli of the lungs.
Approximately two-thirds do not have a known cause (idiopathic),
while one-third result from known endogenous or exogenous
causes, including environmental/occupational factors, infections,
drugs and radiation. Variation in the classification of ILDs, both
historically and internationally, has not aided diagnosis, but recent
consensus guidelines to both diagnosis and classification, together
with a new nomenclature, offer an opportunity for greater
precision. In the light of this new classification, this review
examines the epidemiology of ILD and the evidence for its
potential increase in prevalence.
CLASSIFICATION AND DIAGNOSIS OF ILD
A considerable advance has occurred in the recent consensus
document on the definition of ILD, which is also known as diffuse
parenchymal lung disease. Interstitial lung disease encompasses a
range of disorders, the most common of which is idiopathic
interstitial pneumonia (IIP) (American Thoracic Society, 2002).
Idiopathic interstitial pneumonia is a distinct disease that can be
classified into seven types (Table 1) (American Thoracic Society,
2002).
The new classification has been devised to overcome the lack of
an international standard that has resulted in variable and
confusing diagnostic criteria and nomenclature. Internationally,
there had been many different terms for ILD; for example, in Japan
the term interstitial pneumonia (IP) was used, while cryptogenic
fibrosing alveolitis (CFA) was in use in the UK but idiopathic
pulmonary fibrosis (IPF) was preferred in the USA. The preferred
old terms were IPF and CFA, with IP often used interchangeably
(Katzenstein and Myers, 1998; Poletti and Kitaichi, 2000).
Nonstandard disease classifications have created difficulties in
determining the rates of prevalence and incidence of ILD.
Internationally, as coding for the disease has varied, it has proved
quite difficult to apply the new classification to the many
population registers.
Despite the guidelines for diagnosis with clearly described
criteria, ILD remains a diagnosis of exclusion requiring extensive
investigation, which is seldom possible. Many investigations are
required to differentiate ILD from other diseases (Chernecky and
Sarna, 2000). Infections can be ruled out through blood cultures,
sputum and urine analyses, echocardiography can assess the
likelihood of cardiac oedema and bronchoscopy, while bronch-
oalveolar lavage can reveal pulmonary haemorrhage. High-
resolution computed tomography (HRCT) and pulmonary func-
tion tests are the main tests used to indicate parenchymal lung
disease. However, the definitive investigation is a lung biopsy with
detailed histopathology (Katzenstein and Myers, 1998). In clinical
practice, only a small percentage of patients undergo lung biopsy,
reflecting concerns about the complication of the procedure that
includes prolonged pneumothorax (Hunninghake et al, 2001) and
the fact that many patients are old and infirm.
When ILD is suspected, with use of clinical criteria and CT the
sensitivity of the procedure is 72–77%, while specificity is higher *Correspondence: Professor G Raghu; E-mail: graghu@u.washington.edu
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these investigations (Hunninghake et al, 2001). While we have no
information on the use of these investigations when a patient has
ILD as a comorbidity of another disease, such as lung cancer, it is
likely to be of similar efficacy.
Incidence and prevalence rates for ILD
It is not possible to precisely estimate the incidence and prevalence
rates of ILD for the previously given reasons. In addition, much of
the available data are taken from registries or hospital clinics and
therefore suffer from selection biases, making them unrepresenta-
tive of the general population (Mapel et al, 1998).
The most important registry study was undertaken in Bernalillo
County, New Mexico, USA, using data from a dedicated ILD
registry and employing broad case-identification procedures and
systematic chart review (Coultas et al, 1994). The estimated
incidence of ILD was 30 per 100000 per year, with approximately
one-third in the IPF category; the estimated incidence was slightly
higher for men than women (Table 2) (Coultas et al, 1994). The
estimated prevalence of ILD was almost three times as high as the
incidence, which suggests a mean survival of approximately
3 years.
Very little data from population-based registries are available
from other countries. The few published reports suggest interna-
tional differences in the prevalence of IPF. It is estimated to be 4.1
per 100000 in the Japanese Hokkaido registry (Munakata et al,
1994), 7–12 per 100000 in the Czech Republic (Kolek, 1994) and
16–18 per 100000 in the Finnish registry (Hodgson et al, 2002),
compared with 20.2 per 100000 in men and 13.2 per 100000 in
women in Bernalillo County (Coultas et al, 1994). It is unclear
whether these variations reflect the disease prevalence or
differences in registry methodology or completeness of case
ascertainment.
Comparing the Bernalillo County data with earlier US estimates
suggests an increase in the prevalence of IPF from 3–5 per 100000
in 1984 (Crystal et al, 1984) to 20.2 and 13.2 per 100000 in men
and women, respectively, in 1994 (Coultas et al, 1994). This might
reflect a true increase in IPF prevalence over 10 years, but it is also
likely that earlier studies underestimated IPF prevalence because
they were based on selected populations and because there was less
awareness of ILD (Coultas et al, 1994). The advent of HRCT may
have contributed to this increase in rate.
Mortality data have also been reported to show increasing trends
in CFA and IPF mortality in England, Wales, Scotland, Australia
and Canada, stable mortality rates in New Zealand and Germany,
and a decrease in CFA mortality in the USA (Hubbard et al, 1996),
although the latter may be due to coding practices as mortality
from pulmonary fibrosis overall in the USA increased during the
same period (Mannino et al, 1996). Even though these trends were
not apparently due to changes in diagnostic criteria, mortality data
are biased as they are based on death certificates that under-report
the incidence and prevalence of ILD (Coultas and Hughes, 1996).
In line with these observed increases in the prevalence of ILDs, a
recent study of the healthcare cost has shown a rise in rates. This
retrospective cohort study of IPF was conducted using the
integrated database of medical and pharmacy claims from private
health plans in the USA from January 1996 to December 2000
(Weycker et al, 2002). Analyses were conducted using both a broad
case definition (a medical claim with a diagnosis of IPF and no
subsequent medical claim with diagnoses of other ILDs) and a
narrow case definition (the same as the broad case definition, but
with a medical claim for lung biopsy or CT of the thorax).
Prevalence of IPF was determined from the existing number of
health plan members with IPF in 2000, and incidence of IPF was
determined from the number of newly diagnosed cases in 2000 and
related to population size. Healthcare use and charges were
estimated using all paid medical fees and pharmacy claims for 2000
for these IPF cases.
In keeping with the population-based reports above and the
registries, the prevalence of IPF was estimated at 54 per 100000
adults using the broad case definition and 17 per 100000 adults
using the narrow case definition. Idiopathic pulmonary fibrosis
prevalence increased with age, with most patients aged X65 years.
Idiopathic pulmonary fibrosis incidence for 2000 was estimated to
be 25 per 100000 per year using the broad case definition and 10
per 100000 per year using the narrow case definition. From what is
known of clinical practice, the narrow definition is likely to be a
lower limit estimate of the true occurrence of disease. The broad
definition will probably include some false positives but will also
have o100% specificity, so it may well be closer to the true
incidence and prevalence. Overall, these data are consistent with
the estimates from New Mexico (Coultas et al, 1994).
Table 1 Classification of IIPs (American Thoracic Society, 2002)
IPF/CFA IIP other than IPF
Desquamative interstitial pneumonia
Acute interstitial pneumonia
Nonspecific interstitial pneumonia
Respiratory bronchiolitis interstitial lung disease
Cryptogenic organising pneumonia
Lymphocytic interstitial pneumonia
Table 2 Prevalence in 1988 and incidence in 1988–1990 of ILD in New Mexico (Coultas et al, 1994)
Prevalence per 100000 (n) Incidence per 100000 per year (n)
ILD category Men Women Men Women
Occupational/environmental 20.8 (35) 0.6 (1) 6.2 (21) 0.8 (3)
Drug/radiation 1.2 (2) 2.2 (4) 1.8 (6) 1.1 (4)
Pulmonary haemorrhage syndromes 0.6 (1) 2.2 (4) 1.5 (5) 0.8 (3)
Connective tissue disease 7.1 (12) 11.6 (21) 2.1 (7) 3.0 (11)
Pulmonary fibrosis
Fibrosis (post-inflammatory) 10.1 (17) 14.3 (26) 3.9 (13) 4.1 (15)
IPF 20.2 (34) 13.2 (24) 10.7 (36) 7.4 (27)
Interstitial pneumonitis 1.8 (3) 2.8 (5) 1.8 (6) 1.4 (6)
Sarcoidosis 8.3 (14) 8.8 (16) 0.9 (3) 3.6 (13)
Other 10.7 (18) 11.6 (21) 2.7 (9) 3.9 (14)
Total 80.9 (136) 67.2 (122) 31.5 (106) 26.1 (96)
n¼number of cases in registry. Reprinted with permission from Coultas DB et al (1994). Copyright r 1994 American Lung Association.
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estimated at US$33304 and US$40707 per patient, based on the
broad and narrow case definitions, respectively. Hospital admis-
sions accounted for the main part of costs (71–73%), with
outpatient charges accounting for only 20–22% of costs.
Relative frequencies of parenchymal lung diseases
comprising ILD
Several prospective European ILD registries have been established
(Roelandt et al, 1995; Schweisfurth, 1996; Rizzato and Bariffi, 1999;
Agostini et al, 2001; Thomeer et al, 2001a). Although these
selective registries do not have complete case ascertainment in a
defined population and thus are likely to underestimate the
prevalence or incidence of ILD, they may allow useful comparisons
of the relative frequency of the subcategories of diseases that make
up ILD. Comparison of registries in Belgium, Italy and Germany,
and in Bernalillo County highlighted similarities and differences
(Table 3) (Thomeer et al, 2001b).
While IPF was a common subcategory of ILD in all registries,
sarcoidosis made up a larger proportion of reported ILD cases in
the European registries than the US registry (Demedts et al, 2001;
Thomeer et al, 2001b). ILDs related to occupational and
environmental exposures constituted a smaller proportion of
registered ILD cases in the Italian registry than the other registries.
Environmental factors that contribute to ILD
It is necessary to seek an explanation for these apparent
international differences in the prevalence rates of the various
forms of ILD and the potentially rising world rate. There are a
number of important risk factors for ILD, cigarette smoking being
the most common exposure associated with increased risk (Iwai
et al, 1994; Baumgartner et al, 1997; Britton and Hubbard, 2000;
Nagai et al, 2000). This is in contrast to occupational exposure,
which is diminishing as a risk factor as a result of improved
working environments. The most commonly recognised risk
factors are exposure to dust from metal, wood, vegetables and
animals, although exposures related to hairdressing, raising birds,
and stone cutting and polishing have also been associated with
ILDs (Iwai et al, 1994; Hubbard et al, 1996, 2000a; Baumgartner
et al, 2000).
Pulmonary fibrosis and ILD can occur as a complication of
certain drug exposures, including antidepressants, antiarrythmics
(amiodarone), beta blockers, antibiotics, chemotherapeutic agents
(e.g. bleomycin, mitomycin, cyclophosphamide and methotrexate),
anticonvulsants and nonsteroidal anti-inflammatory drugs (Hub-
bard et al, 1998, 2000b; Foucher et al, 2003). There is even evidence
that remote exposure to nonsteroidal anti-inflammatory drugs
may be an aetiological factor that leads to pulmonary fibrosis later
in life. However, clear and increased risks have been demonstrated
with only a few drugs. This illustrates the value of careful clinical
history taking. It also clearly shows the need for epidemiological
work for agents such as those used for chemotherapy.
An association between CFA and Epstein–Barr virus has also
been suggested (Vergnon et al, 1984). Indeed, there are data to
associate other viral infections with ILD; for example, in Japan
hepatitis C infection is a common association (Ueda et al, 1992).
It can be concluded that there is no single explanation for the
apparent increased prevalence of ILD and for the differences
between nations.
ILD AS A COMORBIDITY OF LUNG CANCER
The association between ILD and lung cancer has been recognised
since 1952 (Callahan et al, 1952). Whether ILD precedes lung
cancer or vice versa, or if both sequences are common, remains
unclear.
Lung cancer in ILD patients
Idiopathic pulmonary fibrosis patients have a higher incidence of
lung cancer than the general population, with relative risks of 7.3
and 14.1 being reported in UK follow-up studies and a similar ratio
of 5.3 for prevalence of lung cancer at death in a small Japanese
autopsy study (Turner-Warwick et al, 1980; Matsushita et al, 1995;
Hubbard et al, 2000c) (Table 4). The prevalence of lung cancer at
Table 3 Comparison of subcategories of ILD across ILD/fibrosis registries (Thomeer et al, 2001b)
Proportion of all ILD cases in registry, %
Prevalent cases Incident cases
ILD category New Mexico Belgium Italy New Mexico Belgium Germany
Total ILD cases, n 258 362 1138 202 264 234
Occupational/environmental
Coal workers pneumoconiosis 3 NR NR 0 NR 0.4
Other pneumoconiosis (asbestosis, silicosis, cobalt, etc.) 11 6 NR 10 7 2
Hypersensitivity pneumonitis 0 13 4 1 12 11
Drug 2 3 2
a 35 3
Radiation 0.4 NR 1 NR NR
Pulmonary haemorrhage syndromes (Goodpasture
syndrome, Wegener granulomatosis and Churg–Strauss
syndrome)
112 3 2 1
Connective tissue disease 13 7 NR 9 7 2
Sarcoidosis 12 31 30 8 26 35
IPF 22 17 37 31 19 32
Pulmonary fibrosis
Fibrosis (post-inflammatory), interstitial pneumonitis 28 NR NR 20 NR NR
ILD, not otherwise defined 3 9 NR 10 10 5
Other (including BOOP, (C)EP, eosinophilic granuloma, etc.) 5 12 25 2 13 8
NR¼not recorded (category not collected or not used); BOOP¼bronchiolitis obliterans organising pneumonia; (C)EP¼chronic eosinophilic pneumonia. Adapted with
permission from Thomeer MJ et al (2001b).Copyright r 2001 European Respiratory Society Journals Ltd.
aDrug plus radiation therapy.
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patient series studies as 6, 17 and 15% (Asada et al, 1992; Takeuchi
et al, 1996; Ogura et al, 1997).
Among those IIP patients initially free of lung cancer, the
approximate cumulative lung cancer incidence over 3–10 years of
follow-up ranged from 6 to 15% in Japanese IIP patient series and
from 4 to 10% in the UK CFA patient series (Turner-Warwick et al,
1980; Ohtsuka et al, 1991; Munakata et al, 1994; Takeuchi et al,
1996; Ogura et al, 1997; Hubbard et al, 2000c).
Many Japanese studies on more or less selected populations of
IIP patients reported a frequency of lung cancer that was mostly a
combination of prevalence and incidence, making them difficult to
interpret. They include two nationwide surveys (8.7 and 19.1%)
and a large number of studies up to 1990 with a range from 8 to
65% and an overall frequency of 27% (reviewed in Takiguchi et al,
1993), as well as some later studies reporting similar frequencies in
the approximate range 20–30% (Nagai et al, 1992; Takeuchi et al,
1996; Ogura et al, 1997).
Idiopathic pulmonary fibrosis patients also have a higher
incidence of lung cancer than patients with chronic obstructive
pulmonary disease (COPD), even though COPD is itself associated
with lung cancer (Samet, 2000). An unadjusted risk ratio of 7.8 for
lung cancer in IPF patients compared with COPD patients was
reported from the Japanese Hokkaido registry data (Ohtsuka et al,
1991; Munakata et al, 1994).
However, two large death-certificate studies from the UK and
the USA did not confirm the association between IPF and lung
cancer risk. These studies found a lower report rate of lung cancer
on the death certificates of individuals with pulmonary fibrosis
mentioned as cause of death on the certificate, than for the general
population or for patients with COPD mentioned (Wells and
Mannino, 1996; Harris et al, 1998). However, death-certificate
studies are problematic because only underlying conditions or
those contributing to the death are coded. Negative bias arises
because lung cancer is more likely to be included on the death
certificate than IPF (Samet, 2000). Data from the Bernalillo County
registry showed that ILD was mentioned on the death certificates
of only 46% of ILD patients and concordance of diagnosis in those
patients was 76% (Coultas and Hughes, 1996).
An explanation of the association between ILD and lung
cancer
Initially, studies focused on the hypothesis that IPF, as a result of
scarring or other proliferative mechanisms, could lead to the
secondary development of lung cancer (Samet, 2000; Ma et al,
2001).
Many occupational and environmental exposures have been
associated with an increased risk of both ILD and lung cancer and
have been investigated as common mechanisms to explain the
association (Samet, 2000). Many studies report that patients with
both IPF and lung cancer are generally heavy smokers (Mizushima
and Kobayashi, 1995; Takeuchi et al, 1996; Aubry et al, 2002).
However, smoking does not appear to fully explain the association
between CFA and lung cancer. Hubbard et al (2000c) found that
the lung cancer rate ratio of 7.3 (95% confidence interval 4.5–11.9)
for CFA patients compared with population controls was not
significantly changed by adjusting for smoking (relative risk 8.3)
or by considering current smokers only (rate ratio 7.4).
As noted, an important hypothesis is that the diffuse
inflammatory process of IPF may increase lung cancer risk
(Samet, 2000). Cryptogenic fibrosing alveolitis produces chronic
inflammation resulting in the remodelling of the lung and
malignancy may be secondary to these chronic inflammatory
and fibrotic processes (Matsushita et al, 1995; Hubbard et al,
2000c). There have been conflicting reports about the type of lung
Table 4 Lung cancer occurrence in ILD and non-ILD populations
Study Country Population n
a
LC
occurrence
(%) Measure
Risk ratio of ILD
vs non-ILD
group or
population
Turner-Warwick et al (1980) UK CFA hospital 205 9.8 CI 5–10 years
General population NA RR 14.1
c
Hubbard et al (2000c) UK CFA GPRD 890 4.4 CI 5 years
Control GPRD 5884 0.9 RR 7.31
d
Munakata et al (1994)
b Japan IIP registry 67 14.9 CI 3.75 years
COPD registry 108 1.9 RR 7.8
c
Asada et al (1992) Japan IIP hospital patient series 212 6.1 Prevalence at diagnosis
Takeuchi et al (1996) Japan IIP patient series 102 16.7 Prevalence at diagnosis
85 7.1 CI 5–10 years
Ogura et al (1997) Japan IIP hospital patients 599 14.9 Prevalence at diagnosis
510 5.7 CI 4 years
Stack et al (1972) UK CFA hospital patients 96 5.2 CI 4 years
Wells and Mannino (1996) USA Pulmonary fibrosis death certificates 4.81 Frequency reported (as underlying
or contributing cause of death)
General population death certificates 6.45 0.74
COPD death certificates 10.1 0.48
Asbestosis death certificates 26.6 0.18
Harris et al (1998) UK Pulmonary fibrosis death certificates 6
Pneumoconiosis death certificates 7 0.86
Silicosis death certificates 8 0.75
Asbestosis death certificates 43 0.14
Matsushita et al (1995) Japan UIP autopsies 83 48.2 Prevalence at autopsy
General autopsies NA 9.1 5.3
Hironaka and Fukayama
(1999)
Japan IPF/UIP autopsy population 70 46 Prevalence at autopsy
LC¼lung cancer; CI¼cumulative incidence; GPRD¼general practice research database; UIP¼usual interstitial pneumonia; NA¼not available.
aSize of study population.
bMunakata et al report an extended follow-up of the population in Ohtsuka et al (1991), where the reported rates after shorter follow-up were slightly higher.
cRR¼relative risk.
dRR¼gender- and age-adjusted rate ratio.
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seen in the general population. Some authors have reported no
difference in the distribution of histological lung cancer types
between patients with and without pulmonary fibrosis (Turner-
Warwick et al, 1980; Park et al, 2001), while others have reported a
distinct anatomical distribution of lung cancer in ILD patients,
with most cancers in the peripheral lung (Matsushita et al, 1995;
Ogura et al, 1997; Ma et al, 2001). Some authors have also reported
a close relationship between the malignancy and honeycombed
fibrotic areas (Matsushita et al, 1995; Hironaka and Fukayama,
1999).
ILD in lung cancer patients
The more recent recognition that ILD develops in lung cancer
patients after radiotherapy and chemotherapy (Takeuchi et al,
1996; Abid et al, 2001; Wang et al, 2001) has raised the question of
whether the association is with the cancer or the treatment.
Therapy-associated ILD may help explain the higher prevalence
of ILD in patient studies, as compared with population studies
where often only palliative care and support were available.
Furthermore, some reports of ILD in lung cancer patients may
represent a worsening or an ‘exacerbation’ of a pre-existing
chronic ILD that has been ‘triggered’ by the cancer therapy
(Kawasaki et al, 2002; Yano et al, 2002).
In reports of hospital patient series from Korea and Japan, IPF
was found in 2% of lung cancer patients (Kinoshita et al, 1990;
Park et al, 2001) and in a review of several earlier Japanese studies,
including that of Kinoshita et al, the overall frequency was
approximately 3%, with some variation across studies (Takiguchi
et al, 1993). Two other Japanese studies, an autopsy study and a
retrospective study of patients following lung cancer resection,
found IPF in 7–8% of these rather selected series of lung cancer
cases (Hironaka and Fukayama, 1999; Kawasaki et al, 2002).
Lung cancer patients have an older age distribution than the
general population and so would be expected to have a higher
frequency of ILD. Diagnosis of ILD occurs mostly in the fifth and
sixth decades, but differs between the ILD diseases, ranging from
the fourth decade for sarcoidosis to the seventh decade for drug-
related ILD (Lim et al, 1996; Johnston et al, 1997; Thomeer et al,
2001a,b). Applying age-specific IPF rates from the Bernalillo
County registry to a population of registered lung cancer cases in
Sweden in 2000 (National Board of Health and Welfare, 2002), an
expected IPF prevalence of around 0.07% and an expected IPF
incidence of o0.04% per year were estimated. While these
predicted rates in a population of lung cancer patients are over
four times higher than in the general population, age distribution
alone does not appear to explain the IPF frequencies of 2–8% in
the selected lung cancer populations reported above.
ILD as a complication of radiotherapy exemplifies the
impact of past exposure to a risk factor
Radiation-associated ILD in non-small-cell lung cancer patients is
well known and follows quite distinctive patterns. Of particular
importance is the ability of radiation therapy to ‘condition’ the
lung to develop ILD after an interval of time. Such a remote
initiating factor can be discovered only if precise records of
therapy are kept.
Classical radiation pneumonitis following single-fraction
radiotherapy
The histopathology of classical radiation pneumonitis after whole-
lung radiotherapy with single doses of X-rays in mice and rats
follows well-defined stages from the latent period, when damage is
only visible by electron microscopy, through to the fibrosis phase,
which develops from 6 months onwards (White, 1975). Classical
radiation pneumonitis is an acute inflammatory response to lung
radiotherapy and is confined to the treated area. Single-dose
radiotherapies of the whole thorax in mice and half-body in
humans have both shown a threshold dose for classical radiation
pneumonitis and a narrow sigmoid dose–response curve with
increasing morbidity and mortality over a very small dose range
(Van Dyk et al, 1981; Travis and Tucker, 1986). In both animal and
human studies, all subjects above the threshold dose eventually
suffer irreversible pulmonary damage and death (Morgan and
Breit, 1995).
Sporadic radiation pneumonitis following fractionated
radiotherapy
In contrast to classical radiation pneumonitis, clinical pneumoni-
tis, which can occur after a fractionated course of radiotherapy to a
portion of the lungs, is characterised by a nonproductive cough
and dyspnoea disproportional to the volume of lung irradiated.
The onset is unpredictable, occurs in only 5–10% of irradiated
humans and usually resolves completely without long-term effects
(Morgan and Breit, 1995). The term ‘sporadic radiation pneumo-
nitis’ has been used to describe this clinical picture, which is
distinct from classical radiation pneumonitis.
There is now evidence that sporadic pneumonitis is charac-
terised by bilateral lymphocytic alveolitis and is actually a
hypersensitivity pneumonitis similar to that seen in farmer’s lung
or methotrexate pneumonitis (Gibson et al, 1988; Abratt and
Morgan, 2002).
Following unilateral thoracic radiotherapy for breast cancer,
bronchoalveolar lavage revealed increases in total cells and in
lymphocytes in both the irradiated lung and the nonirradiated
lung. Gallium scans also increased in intensity bilaterally (Gibson
et al, 1988; Roberts et al, 1993). Although a lymphocytic alveolitis
occurred in all patients, only a minority developed pneumonitis. It
was noticed, however, that the increase in total lymphocytes and in
the gallium index was more pronounced in women with
pneumonitis. Retrospective analysis of the data revealed a more
marked bilateral lymphocytic alveolitis and increase in gallium
lung scan uptake in women with sporadic pneumonitis compared
with those without pneumonitis (Figure 1) (Morgan and Breit,
1995). The generalised lymphocytic response suggests an immu-
nologically mediated response against damaged lung tissue,
analogous to a hypersensitivity pneumonitis.
Pulmonary fibrosis following radiotherapy
Pulmonary fibrosis is a consequence of the repair process
following tissue injury by surgery, radiotherapy, chemotherapy,
infection or acute and chronic inflammatory processes, although a
precise mechanism is unknown.
Tissue repair involves recruitment of fibroblasts, cell replication
and stimulation of fibroblasts to synthesise collagen. In inflam-
matory lung diseases, the spontaneous release of fibroblast growth
factors, chemotactic factors, inflammatory cytokines and fibro-
genic factors have all been documented. Irradiation of mono-
nuclear phagocytes resulted in the dose-dependent synthesis and
release of several growth factors for fibroblasts, including platelet-
derived growth factor (PDGF) b, tumour necrosis factor a and
insulin-like growth factor I. In addition, the in vivo irradiation of
cells obtained by bronchoalveolar lavage from patients just prior to
and 4–6 weeks after thoracic radiotherapy indicated a radiation-
induced release of PDGF (Thornton et al, 1996). These results
suggest that pulmonary fibrosis after therapeutic radiotherapy is
not a consequence of direct damage from ionising radiation but,
instead, arises from the local release of cytokines. It is therefore a
separate event with a different aetiology from sporadic pneumo-
nitis.
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Asada and colleagues described two cases of ‘exacerbation’ of IP
after radiation in patients with lung cancer and IP, diffusely
outside the radiation field. Both patients died, and had also
received chemotherapy (Asada et al, 1992).
ILD as a complication of pulmonary resection
Some cases of ILD in lung cancer patients may occur as an
exacerbation against a predisposing background of a pre-existing
chronic IPF. For example, in one review of 50 patients with a
diagnosis of both IIP and lung cancer who underwent pulmonary
resection, 24% had an acute exacerbation within 30 days and the
mortality in this group was very high (Yano et al, 2002). The rate of
exacerbation was related to the extent of resection, as might be
expected. However, although this was a small study, it is notable
that no significant pre-operative predictive factors were found,
although steroids were suggested to afford some protection. This
review may be biased by the selection of patients reported in the
literature. In another study of 711 consecutive lung cancer
resections, 2 out of 53 (4%) with pre-existing IPF died post-
operatively from exacerbation of IPF, corresponding to 2 out of
711 lung cancer patients (0.28%) (Kawasaki et al, 2002). In a third
similar study of 2667 lung cancer thoracotomies, it was not
reported what proportion had pre-existing IPF, but overall
8 (0.30%) died post-operatively from IP (Tanita et al, 2001),
consistent with Kawasaki et al. Little is known about the rates of
nonfatal ILD after operation. Although it is thus still unclear how
common this complication is in lung cancer patients, and in
particular in those with pre-existing IPF, it is possible that pre-
existing ILD increases the risk of exacerbation after a lung trauma,
due to specific disease processes or simply because of limited
reserve capacity. Such pre-existing lung conditions might similarly
modify susceptibility for other nonoperative treatments affecting
the integrity of the lungs.
SUMMARY
Standardised diagnostic methods and criteria that can be used in
epidemiological studies are urgently needed to ensure consistency
between studies. More prospective studies are required to under-
stand the regional incidence and prevalence of ILD and the
incidence and risk factors for lung cancer in ILD patients.
However, the picture is emerging of an increasing prevalence of
ILD worldwide with some marked international differences. To
explain this simply by improved diagnosis is not sufficient.
There remain the important links between smoking and ILD,
and the links between non-small-cell lung cancer and ILD. These
raise the question of whether the treatment of lung cancer
increases the risk of ILD, which also requires further research.
But here there are important pointers to pre-existing ILD
increasing the chances of an ‘exacerbation’, particularly with
therapies such as radiation and thoracic surgery, but also
potentially chemotherapy.
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